SAB Biotherapeutics (SABS) Current Deferred Revenue (2020 - 2024)
SAB Biotherapeutics (SABS) posted Current Deferred Revenue of $114698.0 for Q3 2024, little changed on a QoQ basis from $114698.0 in Q2 2024, and down 92.95% year-over-year from $1.6 million in Q4 2023.
SAB Biotherapeutics (SABS) Current Deferred Revenue (2020 - 2024) Analysis & Trends
SAB Biotherapeutics' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $114698.0 for Q3 2024.
- Quarterly Current Deferred Revenue fell 92.95% year-over-year to $114698.0 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was $114698.0 (down 92.95% YoY) and the FY2023 annual result came in at $1.3 million, changed N/A from the prior year.
- Current Deferred Revenue was $114698.0 for Q3 2024 at SAB Biotherapeutics, roughly flat from $114698.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $2.9 million in Q1 2023 and bottomed at $100000.0 in Q4 2020.
- A 4-year average of $1.1 million and a median of $377835.0 in 2024 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2021 — Current Deferred Revenue changed 0.0% — and 2024, when it sank 96.04%.
- SAB Biotherapeutics' Current Deferred Revenue stood at $100000.0 in 2020, then changed by 0.0% to $100000.0 in 2021, then jumped by 1222.41% to $1.3 million in 2023, then tumbled by 91.33% to $114698.0 in 2024.
- Business Quant data shows SABS's Current Deferred Revenue at $114698.0 in Q3 2024, $114698.0 in Q2 2024, and $377835.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 114,698.00 |
| Jun 30, 2024 | 114,698.00 |
| Mar 31, 2024 | 377,835.00 |
| Dec 31, 2023 | 1.32 Mn |
| Sep 30, 2023 | 1.63 Mn |
| Jun 30, 2023 | 2.89 Mn |
| Mar 31, 2023 | 2.94 Mn |
| Dec 31, 2021 | 100,000.00 |
| Dec 31, 2020 | 100,000.00 |